

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

JUN 2 8 2002

Mr. Alan Chang Manager, Research and Development Apex Medical Corporation 10<sup>th</sup> Floor, No. 31, Lane 169 Kang-Ning St. Shi-Chih, Taipei Hsien Taiwan, R.O.C.

Re: K021754

Trade/Device Name: Apex Medical Digital EMS, models TS1311 and TS1312

Regulation Number: 21 CFR 890.5850

Regulation Name: Powered muscle stimulator

Regulatory Class: II Product Code: IPF Dated: May 27, 2002 Received: May 29, 2002

Dear Mr. Chang:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

	Page	1	of	1
510(k) Number: K 0 2 1 7 5 4	<b>3</b> * <u>2</u>			
Device Name: Apex Medical Digital EMS TS1311, TS1312 Indications For Use:				
Apex Medical Digital EMS is intended to be used in:  1. Relaxation of Muscle Spasm.  2. Prevention or retardation of disuse atrophy.  3. Increase local blood circulation.  4. Muscle re-education.				
<ul><li>5. Immediate post surgical stimulation of calf muscles to prevent ve</li><li>6. Maintaining or increasing range of motion.</li></ul>	nous thro	omb	osis.	
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON AND NEEDED)	OTHER	PAG	E IF	
Concurrence of CDRH, Office of Device Evaluation (0	DDE)			
Prescription Use OR Over-The-Cou (Per 21 CFR 801.109) (Optional	unter-Us Format 1		- }	

(Division Sign-Off)
Division of General, Restorative
and Neurological Devices K021754

(Optional Format 1-2-96)